Advances of study on prognostic factors of molecular biology in acute myeloid leukemia with normal cytogenetics.
- Author:
Tian-Jie HAN
1
;
Xiao-Ping XU
Author Information
1. Department of Hematology, Huashan Hospital, Fudan University, Shanghai 200040, China.
- Publication Type:Journal Article
- MeSH:
Cytogenetics;
Humans;
Karyotyping;
Leukemia, Myeloid, Acute;
diagnosis;
genetics;
Prognosis
- From:
Journal of Experimental Hematology
2010;18(4):1063-1068
- CountryChina
- Language:Chinese
-
Abstract:
Acute myeloid leukemia (AML) is a group of diseases with a conspicuous heterogeneity. Following the development of cytogenetics, multiple reproducible chromosome aberrations have been discovered in AML, many of which not only are diagnostic markers for specific AML subtypes but also significant prognostic factors for determining complete remission (CR), relapse risk, and overall survival (OS). However, with the foundation of available chromosome analysis, a large group of acute myeloid leukemia (AML) patients, 40% to 49% of adults and 25% of children had not been found abnormality of chromosome karyotype under microscope. These so-called cytogenetically normal acute myeloid leukemia (CN-AML) patients have usually been classified in an intermediate-risk prognostic category. Nevertheless, the outcome of the CN-AML patients are varied in clinical studies, likely because there exist diverse gene mutations in these patients according to recent researches. Those mutations at the molecular level, on basis of which AML could be further classified, are significantly associated with CN-AML patients and offer potential targets for specific therapeutic studies. The review focuses on research advances abroad in this field including gene mutations suggesting bad prognosis such as FMS-related tyrosine kinase 3 gene mutation, Baalc gene and ETS-related gene hyperexpression, Wilms' tumor gene mutation and other gene mutations as well as gene mutations suggesting good prognosis such as nucleophosmin gene mutation, mixed lineage leukemia-partial tandem duplication, CCAAT/enhancer-binding protein α gene mutation.
